Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure

Official title

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure: a Phase II Study

Overview

Prognosis of patients with graft failure is dismal, and re-transplantation is the sole option for long-term survival. Currently, there is no consensus concerning therapeutic options in patients with primary or secondary (within the 60 days post-transplantation) graft failure and finding a new donor within an acceptable delay is challenging. Literature is poor on the subject while the overall survival of such patients is about 30% at 1 year. This situation thus represents today a very challenging unmet medical need. Recently, haploidentical (haplo) related donor Stem Cell Transplantation (haplo-SCT) have improved dramatically outcomes using T-cell replete grafts with administration of post-transplantation cyclophosphamide (PTCy, which targets alloreactive T cells generated early after an HLA-mismatched transplant, sparing regulatory T cells and leaving unaffected the non-dividing hematopoietic stem cells) and standard post-transplant immune suppression with a calcineurin inhibitor (CNI) and mycophenolate mofetil. Our group re-transplanted a patient who experienced two consecutive graft failures and was successfully managed through a third haplo-SCT from her son using PTCy. We then retrospectively collected and analyzed data from 26 primary graft failure patients transplanted between 2011 and 2017 in 15 centers on behalf of French Society for Stem Cell Transplantation and Cell Therapy (SFGM-TC). The study population consisted mainly of patients with primary or secondary (within the 60 days post-transplantation) graft failure who underwent haplo-SCT and received PTCy as graft-versus-host-disease prophylaxis. The 1-year overall survival was about 60% suggesting that this approach might be a valid option in this particular poor clinical situation but now need validation through a phase II multicenter, national, prospective cohort study.

Interventions

• Other haplo-SCT with PTCy
  Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide \>100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1). Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 2

Primary outcome measures

• Overall Survival [Time frame: at one year]

Secondary outcome measures (12)

• Graft failure incidence [Time frame: at 3 months]
• Neutrophils engraftment [Time frame: at day 100]
• Platelets engraftment [Time frame: at day 100]
• Absolute numbers of neutrophils [Time frame: at 1 month]
• Absolute numbers of neutrophils [Time frame: at 2 months]
• Absolute numbers of neutrophils [Time frame: at 3 months]
• Absolute numbers of neutrophils [Time frame: at 6 months]
• Absolute numbers of neutrophils [Time frame: at 12 months]
• Absolute numbers of neutrophils [Time frame: through study completion, an average of 6 months]
• Absolute number of platelets [Time frame: at one month]
• Absolute number of platelets [Time frame: at 2 months]
• Absolute number of platelets [Time frame: at 3 months]

Eligibility criteria

Inclusion criteria

• Aged from 3 to 70 years
• All hematological diseases
• Suffering from primary or secondary (within the 60 days post-transplantation) graft failure after a 1st allo-SCT
• With usual criteria for allo-SCT:

• ECOG ≤ 2
• No severe and uncontrolled infection
• Cardiac function compatible with high dose of cyclophosphamide
• Adequate organ function: ASAT and ALAT ≤ 2.5N, total bilirubin ≤ 2N, creatinine clearance ≥30ml / min
• With identification of a haploidentical donor (brother, sister, parents, adult children or cousin)
• Absence of donor specific antibody (DSA) detected in the patient with a MFI ≥ 1500 (antibodies directed towards the distinct haplotype between donor and recipient)
• With health insurance coverage (bénéficiaire ou ayant droit).
• Understand informed consent or optimal treatment and follow-up.
• Contraception methods must be prescribed during all the duration of the research. Women and men of childbearing age must use contraceptive methods within 12 months and 6 months after the last dose of cyclophosphamide, respectively.
• Having signed a written informed consent (2 parents for patients aged less than 18)

Exclusion criteria

• Aged< 3 years old and >70 years old
• With uncontrolled infection
• With Seropositivity for HIV or HTLV-1 or active hepatitis B or C defined by a positive PCR HBV or HCV and associated hepatic cytolysis
• Yellow fever vaccine within 2 months before transplantation
• Cancer in the last 5 years (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix)
• Uncontrolled coronary insufficiency, recent myocardial infarction <6 month, current manifestations of heart failure, uncontrolled cardiac rhythm disorders, ventricular ejection fraction <50%
• Heart failure according to NYHA (II or more)
• Preexisting acute hemorrhagic cystitis
• Renal failure with creatinine clearance < 30ml / min
• Urinary tract obstruction
• Pregnant (β-HCG positive) or breast-feeding
• Who have any debilitating medical or psychiatric illness, which preclude understanding the inform consent as well as optimal treatment and follow-up
• COVID vaccination or recent COVID disease <3 months
• Tutorship or curatorship
• Contraindications to treatments used during the research

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05126186 · APHP200129

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗